Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201805 | 0.92 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3642785 | 0.92 | MAOA (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL27429142 | 0.86 | TDP1 (0.50) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL15931183 | 0.85 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21962098 | 0.84 | MEN1 (0.50) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL125503 | 0.84 | TDP1 (0.52) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL4714065 | 0.84 | TDP1 (0.52) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL6234096 | 0.83 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL18618701 | 0.83 | TDP1 (0.47) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3131272 | 0.83 | TDP1 (0.47) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751867-A | Feed additive capable of improving immunity and preparation method and application thereof | 河南湾流生物科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-105018541-B | (S) synthetic method of the hydroxy propyl carbamate of the tert-butyl group 2 | 上海合全药物研发有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-105018541-A | Synthetic method of (S)-t-butyl-2-hydroxypropylcarbamate | SHANGHAI SYNTHEALL PHARMACEUTICALS RES CO LTD | 2015-11-04 | — | — | CN | claimed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058452-B1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2025-07-09 | — | — | EP | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-20070099841-A1 | Prodrugs of T3 and T4 with enhanced bioavailability | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1771443-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006104356-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES, LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006002828-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
| CN-1202096-C | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2005-05-18 | — | — | CN | disclosed |
| CN-1444572-A | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-24 | — | — | CN | disclosed |
| WO-1995033724-A1 | PHENETHANOLAMINE DERIVATIVES AND THEIR USE AS ATYPICAL BETA-ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | TDP1 3482/4885MAOA 353/4885MAOB 372/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | TDP1 473/4885MAOA 4171/4885MAOB 3963/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | TDP1 388/4885MAOA 1338/4885MAOB 1041/4885 |
| US-20070099841-A1 | Prodrugs of T3 and T4 with enhanced bioavailability | THRA, THRB, SLC7A1 | TDP1 723/4885MAOA 2604/4885MAOB 1940/4885 |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | TDP1 787/4885MAOA 4524/4885MAOB 4378/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | TDP1 3609/4885MAOA 4857/4885MAOB 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.